The role and future of FFA1 as a therapeutic target

Handbook of Experimental Pharmacology

Volumn 236, Issue , 2017, Pages 159-180

  Ghislain, Julien ^a,b   Poitout, Vincent ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Allosteric agonist; Biased agonism; FFA1 Gpr40; Functional selectivity; Insulin secretion; Pancreatic islet; Type 2 diabetes; cell

Indexed keywords

AM 1638; AM 5262; AM 8182; AMG 837; ANT 203; AS 2034178; CNX 011 67; CYTOKINE RECEPTOR AGONIST; CYTOKINE RECEPTOR ANTAGONIST; DOCOSAHEXAENOIC ACID; FASIGLIFAM; G PROTEIN COUPLED RECEPTOR 40; GLIMEPIRIDE; GW 9508; INSULIN; LY 2881835; METFORMIN; PLACEBO; TUG 424; UNCLASSIFIED DRUG; BENZOFURAN DERIVATIVE; FFAR1 PROTEIN, HUMAN; G PROTEIN COUPLED RECEPTOR; SULFONE; TAK-875;

ALLOSTERISM; ANTIINFLAMMATORY ACTIVITY; CELL PROTECTION; DIABETES MELLITUS; DIET THERAPY; DOSE RESPONSE; DRUG BINDING SITE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; EXERCISE; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; LIGAND BINDING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STIMULUS SECRETION COUPLING; UNSPECIFIED SIDE EFFECT; AGONISTS; ANIMAL; DIABETES MELLITUS, TYPE 2; METABOLIC DISEASES; PHYSIOLOGY; SECRETION (PROCESS);

ANIMALS; BENZOFURANS; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN; INSULIN-SECRETING CELLS; METABOLIC DISEASES; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; SULFONES;

EID: 85014079894     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/164_2016_51     Document Type: Chapter

References (100)

1. Ahren B (2009) Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov 8:369-385. doi:10.1038/nrd2782
2. Alquier T, Peyot ML, Latour MG, Kebede M, Sorensen CM, Gesta S, Ronald Kahn C, Smith RD, Jetton TL, Metz TO, Prentki M, Poitout V (2009) Deletion of GPR40 impairs glucose-induced insulin secretion in vivo in mice without affecting intracellular fuel metabolism in islets. Diabetes 58:2607-2615. doi:10.2337/db09-0362
3. Amisten S, Salehi A, Rorsman P, Jones PM, Persaud SJ (2013) An atlas and functional analysis of G-protein coupled receptors in human islets of Langerhans. Pharmacol Ther 139:359-391. doi:10.1016/j.pharmthera.2013.05.004
4. Araki T, Hirayama M, Hiroi S, Kaku K (2012) GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes. Diabetes Obes Metab 14:271-278. doi:10.1111/j.1463-1326.2011.01525.x
5. Boneva NB, Yamashima T (2012) New insights into “GPR40-CREB interaction in adult neurogenesis” specific for primates. Hippocampus 22:896-905. doi:10.1002/hipo.20951
6. Briscoe CP, Tadayyon M, Andrews JL, Benson WG, Chambers JK, Eilert MM, Ellis C, Elshourbagy NA, Goetz AS, Minnick DT, Murdock PR, Sauls HR Jr, Shabon U, Spinage LD, Strum JC, Szekeres PG, Tan KB, Way JM, Ignar DM, Wilson S, Muir AI (2003) The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem 278:11303-11311. doi:10.1074/jbc.M211495200
7. Brown SP, Dransfield PJ, Vimolratana M, Jiao X, Zhu L, Pattaropong V, Sun Y, Liu J, Luo J, Zhang J, Wong S, Zhuang R, Guo Q, Li F, Medina JC, Swaminath G, Lin DC, Houze JB (2012) Discovery of AM-1638: a potent and orally bioavailable GPR40/FFA1 full agonist. ACS Med Chem Lett 3:726-730. doi:10.1021/ml300133f
8. Burant CF, Viswanathan P, Marcinak J, Cao C, Vakilynejad M, Xie B, Leifke E (2012) TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 379:1403-1411. doi:10.1016/s0140-6736(11)61879-5
9. Cartoni C, Yasumatsu K, Ohkuri T, Shigemura N, Yoshida R, Godinot N, le Coutre J, Ninomiya Y, Damak S (2010) Taste preference for fatty acids is mediated by GPR40 and GPR120. J Neurosci 30:8376-8382. doi:10.1523/jneurosci.0496-10.2010
10. Cornish J, MacGibbon A, Lin JM, Watson M, Callon KE, Tong PC, Dunford JE, van der Does Y, Williams GA, Grey AB, Naot D, Reid IR (2008) Modulation of osteoclastogenesis by fatty acids. Endocrinology 149:5688-5695. doi:10.1210/en.2008-0111
11. Defossa E, Wagner M (2014) Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus. Bioorg Med Chem Lett 24:2991-3000. doi:10.1016/j.bmcl.2014.05.019
12. Del Guerra S, Bugliani M, D’Aleo V, Del Prato S, Boggi U, Mosca F, Filipponi F, Lupi R (2010) G-protein-coupled receptor 40 (GPR40) expression and its regulation in human pancreatic islets: the role of type 2 diabetes and fatty acids. Nutr Metab Cardiovasc Dis 20:22-25. doi:10.1016/j.numecd.2009.02.008
13. Edfalk S, Steneberg P, Edlund H (2008) Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 57:2280-2287. doi:10.2337/db08-0307
14. El-Azzouny M, Evans CR, Treutelaar MK, Kennedy RT, Burant CF (2014) Increased glucose metabolism and glycerolipid formation by fatty acids and GPR40 receptor signaling underlies the fatty acid potentiation of insulin secretion. J Biol Chem 289:13575-13588. doi:10.1074/jbc.M113.531970
15. Ferdaoussi M, Bergeron V, Zarrouki B, Kolic J, Cantley J, Fielitz J, Olson EN, Prentki M, Biden T, MacDonald PE, Poitout V (2012) G protein-coupled receptor (GPR)40-dependent potentiation of insulin secretion in mouse islets is mediated by protein kinase D1. Diabetologia 55:2682-2692. doi:10.1007/s00125-012-2650-x
16. Flodgren E, Olde B, Meidute-Abaraviciene S, Winzell MS, Ahren B, Salehi A (2007) GPR40 is expressed in glucagon producing cells and affects glucagon secretion. Biochem Biophys Res Commun 354:240-245. doi:10.1016/j.bbrc.2006.12.193
17. Fontes G, Zarrouki B, Hagman DK, Latour MG, Semache M, Roskens V, Moore PC, Prentki M, Rhodes CJ, Jetton TL, Poitout V (2010) Glucolipotoxicity age-dependently impairs beta cell function in rats despite a marked increase in beta cell mass. Diabetologia 53:2369-2379. doi:10.1007/s00125-010-1850-5
18. Fujita T, Matsuoka T, Honda T, Kabashima K, Hirata T, Narumiya S (2011) A GPR40 agonist GW9508 suppresses CCL5, CCL17, and CXCL10 induction in keratinocytes and attenuates cutaneous immune inflammation. J Invest Dermatol 131:1660-1667. doi:10.1038/jid.2011.123
19. Fujiwara K, Maekawa F, Yada T (2005) Oleic acid interacts with GPR40 to induce Ca2+ signaling in rat islet beta-cells: mediation by PLC and L-type Ca2+ channel and link to insulin release. Am J Physiol Endocrinol Metab 289:E670-E677. doi:10.1152/ajpendo.00035.2005
20. Gosmain Y, Cheyssac C, Masson MH, Guerardel A, Poisson C, Philippe J (2012) Pax6 is a key component of regulated glucagon secretion. Endocrinology 153:4204-4215. doi:10.1210/en.2012-1425
21. Gowda N, Dandu A, Singh J, Biswas S, Raghav V, Lakshmi MN, Shilpa PC, Sunil V, Reddy A, Sadasivuni M, Aparna K, Verma MK, Moolemath Y, Anup MO, Venkataranganna MV, Somesh BP, Jagannath MR (2013) Treatment with CNX-011-67, a novel GPR40 agonist, delays onset and progression of diabetes and improves beta cell preservation and function in male ZDF rats. BMC Pharmacol Toxicol 14:28. doi:10.1186/2050-6511-14-28
22. Guo S, Zhang J, Zhang S, Li J (2015) A single amino acid mutation (R104P) in the E/DRY motif of GPR40 impairs receptor function. PLoS One 10, e0141303. doi:10.1371/journal.pone.0141303
23. Hamid YH, Vissing H, Holst B, Urhammer SA, Pyke C, Hansen SK, Glumer C, Borch-Johnsen K, Jorgensen T, Schwartz TW, Pedersen O, Hansen T (2005) Studies of relationships between variation of the human G protein-coupled receptor 40 gene and type 2 diabetes and insulin release. Diabet Med 22:74-80. doi:10.1111/j.1464-5491.2005.01505.x
24. Hauge M, Vestmar MA, Husted AS, Ekberg JP, Wright MJ, Di Salvo J, Weinglass AB, Engelstoft MS, Madsen AN, Luckmann M, Miller MW, Trujillo ME, Frimurer TM, Holst B, Howard AD, Schwartz TW (2015) GPR40 (FFAR1) - combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo. Mol Metab 4:3-14. doi:10.1016/j.molmet.2014.10.002
25. Honore JC, Kooli A, Hamel D, Alquier T, Rivera JC, Quiniou C, Hou X, Kermorvant-Duchemin E, Hardy P, Poitout V, Chemtob S (2013) Fatty acid receptor Gpr40 mediates neuromicrovascular degeneration induced by transarachidonic acids in rodents. Arterioscler Thromb Vasc Biol 33:954-961. doi:10.1161/atvbaha.112.300943
26. Houze JB, Zhu L, Sun Y, Akerman M, Qiu W, Zhang AJ, Sharma R, Schmitt M, Wang Y, Liu J, Liu J, Medina JC, Reagan JD, Luo J, Tonn G, Zhang J, Lu JY, Chen M, Lopez E, Nguyen K, Yang L, Tang L, Tian H, Shuttleworth SJ, Lin DC (2012) AMG 837: a potent, orally bioavailable GPR40 agonist. Bioorg Med Chem Lett 22:1267-1270. doi:10.1016/j.bmcl.2011.10.118
27. Hu H, He LY, Gong Z, Li N, Lu YN, Zhai QW, Liu H, Jiang HL, Zhu WL, Wang HY (2009) A novel class of antagonists for the FFAs receptor GPR40. Biochem Biophys Res Commun 390:557-563. doi:10.1016/j.bbrc.2009.10.004
28. Ito R, Tsujihata Y, Matsuda-Nagasumi K, Mori I, Negoro N, Takeuchi K (2013) TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and beta-cell dysfunction in Zucker diabetic fatty rats. Br J Pharmacol 170:568-580. doi:10.1111/bph.12297
29. Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, Ogi K, Hosoya M, Tanaka Y, Uejima H, Tanaka H, Maruyama M, Satoh R, Okubo S, Kizawa H, Komatsu H, Matsumura F, Noguchi Y, Shinohara T, Hinuma S, Fujisawa Y, Fujino M (2003) Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 422:173-176. doi:10.1038/nature01478
30. Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840-846. doi:10.1038/nature05482
31. Kaku K, Araki T, Yoshinaka R (2013) Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes. Diabetes Care 36:245-250. doi:10.2337/dc12-0872
32. Kaku K, Enya K, Nakaya R, Ohira T, Matsuno R (2015) Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes Metab 17:675-681. doi:10.1111/dom.12467
33. Kalis M, Leveen P, Lyssenko V, Almgren P, Groop L, Cilio CM (2007) Variants in the FFAR1 gene are associated with beta cell function. PLoS One 2, e1090. doi:10.1371/journal.pone.0001090
34. Kebede M, Alquier T, Latour MG, Semache M, Tremblay C, Poitout V (2008) The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Diabetes 57:2432-2437. doi:10.2337/db08-0553
35. Kebede M, Ferdaoussi M, Mancini A, Alquier T, Kulkarni RN, Walker MD, Poitout V (2012) Glucose activates free fatty acid receptor 1 gene transcription via phosphatidylinositol-3- kinase-dependent O-GlcNAcylation of pancreas-duodenum homeobox-1. Proc Natl Acad Sci USA 109:2376-2381.doi:10.1073/pnas.1114350109
36. Khan MZ, He L (2015) The role of polyunsaturated fatty acids and GPR40 receptor in brain. Neuropharmacology. doi:10.1016/j.neuropharm.2015.05.013
37. Khan MZ, Zhuang X, He L (2016) GPR40 receptor activation leads to CREB phosphorylation and improves cognitive performance in an Alzheimer’s disease mouse model. Neurobiol Learn Mem 131:46-55. doi:10.1016/j.nlm.2016.03.006
38. Kim HS, Hwang YC, Koo SH, Park KS, Lee MS, Kim KW, Lee MK (2013) PPAR-gamma activation increases insulin secretion through the up-regulation of the free fatty acid receptor GPR40 in pancreatic beta-cells. PLoS One 8, e50128. doi:10.1371/journal.pone.0050128
39. Kotarsky K, Nilsson NE, Flodgren E, Owman C, Olde B (2003) A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. Biochem Biophys Res Commun 301:406-410
40. Kristinsson H, Smith DM, Bergsten P, Sargsyan E (2013) FFAR1 is involved in both the acute and chronic effects of palmitate on insulin secretion. Endocrinology 154:4078-4088. doi:10.1210/en.2013-1352
41. Kristinsson H, Bergsten P, Sargsyan E (2015) Free fatty acid receptor 1 (FFAR1/GPR40) signaling affects insulin secretion by enhancing mitochondrial respiration during palmitate exposure. Biochim Biophys Acta 1853:3248-3257. doi:10.1016/j.bbamcr.2015.09.022
42. Lan H, Hoos LM, Liu L, Tetzloff G, Hu W, Abbondanzo SJ, Vassileva G, Gustafson EL, Hedrick JA, Davis HR (2008) Lack of FFAR1/GPR40 does not protect mice from high-fat diet-induced metabolic disease. Diabetes 57:2999-3006. doi:10.2337/db08-0596
43. Latour MG, Alquier T, Oseid E, Tremblay C, Jetton TL, Luo J, Lin DC, Poitout V (2007) GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes 56:1087-1094. doi:10.2337/db06-1532
44. Li Z, Qiu Q, Xu X, Wang X, Jiao L, Su X, Pan M, Huang W, Qian H (2016) Design, synthesis and structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes. Eur J Med Chem 113:246-257. doi:10.1016/j.ejmech.2016.02.040
45. Lin DC, Zhang J, Zhuang R, Li F, Nguyen K, Chen M, Tran T, Lopez E, Lu JY, Li XN, Tang L, Tonn GR, Swaminath G, Reagan JD, Chen JL, Tian H, Lin YJ, Houze JB, Luo J (2011) AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents. PLoS One 6, e27270. doi:10.1371/journal.pone.0027270
46. Lin DC, Guo Q, Luo J, Zhang J, Nguyen K, Chen M, Tran T, Dransfield PJ, Brown SP, Houze J, Vimolratana M, Jiao XY, Wang Y, Birdsall NJ, Swaminath G (2012) Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor. Mol Pharmacol 82:843-859. doi:10.1124/mol.112.079640
47. Liou AP, Lu X, Sei Y, Zhao X, Pechhold S, Carrero RJ, Raybould HE, Wank S (2011) The G- protein-coupled receptor GPR40 directly mediates long-chain fatty acid-induced secretion of cholecystokinin. Gastroenterology 140:903-912. doi:10.1053/j.gastro.2010.10.012
48. Luo J, Swaminath G, Brown SP, Zhang J, Guo Q, Chen M, Nguyen K, Tran T, Miao L, Dransfield PJ, Vimolratana M, Houze JB, Wong S, Toteva M, Shan B, Li F, Zhuang R, Lin DC (2012) A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents. PLoS One 7, e46300. doi:10.1371/journal.pone.0046300
49. Ma D, Lu L, Boneva NB, Warashina S, Kaplamadzhiev DB, Mori Y, Nakaya MA, Kikuchi M, Tonchev AB, Okano H, Yamashima T (2008) Expression of free fatty acid receptor GPR40 in the neurogenic niche of adult monkey hippocampus. Hippocampus 18:326-333. doi:10.1002/hipo.20393
50. Mancini AD, Poitout V (2013) The fatty acid receptor FFA1/GPR40 a decade later: how much do we know? Trends Endocrinol Metab 24:398-407. doi:10.1016/j.tem.2013.03.003
51. Mancini AD, Bertrand G, Vivot K, Carpentier E, Tremblay C, Ghislain J, Bouvier M, Poitout V (2015) beta-Arrestin recruitment and biased agonism at free fatty acid receptor 1. J Biol Chem 290:21131-21140. doi:10.1074/jbc.M115.644450
52. Matsuda-Nagasumi K, Takami-Esaki R, Iwachidow K, Yasuhara Y, Tanaka H, Ogi K, Nakata M, Yano T, Hinuma S, Taketomi S, Odaka H, Kaisho Y (2013) Lack of GPR40/FFAR1 does not induce diabetes even under insulin resistance condition. Diabetes Obes Metab 15:538-545. doi:10.1111/dom.12065
53. McDonald PH, Lefkowitz RJ (2001) Beta-Arrestins: new roles in regulating heptahelical receptors’ functions. Cell Signal 13:683-689
54. Meidute Abaraviciene S, Muhammed SJ, Amisten S, Lundquist I, Salehi A (2013) GPR40 protein levels are crucial to the regulation of stimulated hormone secretion in pancreatic islets. Lessons from spontaneous obesity-prone and non-obese type 2 diabetes in rats. Mol Cell Endocrinol 381:150-159. doi:10.1016/j.mce.2013.07.025
55. Mieczkowska A, Basle MF, Chappard D, Mabilleau G (2012) Thiazolidinediones induce osteocyte apoptosis by a G protein-coupled receptor 40-dependent mechanism. J Biol Chem 287:23517-23526. doi:10.1074/jbc.M111.324814
56. Nagasumi K, Esaki R, Iwachidow K, Yasuhara Y, Ogi K, Tanaka H, Nakata M, Yano T, Shimakawa K, Taketomi S, Takeuchi K, Odaka H, Kaisho Y (2009) Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes 58:1067-1076. doi:10.2337/db08-1233
57. Nakamoto K, Nishinaka T, Matsumoto K, Kasuya F, Mankura M, Koyama Y, Tokuyama S (2012) Involvement of the long-chain fatty acid receptor GPR40 as a novel pain regulatory system. Brain Res 1432:74-83. doi:10.1016/j.brainres.2011.11.012
58. Nakamoto K, Nishinaka T, Sato N, Mankura M, Koyama Y, Kasuya F, Tokuyama S (2013) Hypothalamic GPR40 signaling activated by free long chain fatty acids suppresses CFA-induced inflammatory chronic pain. PLoS One 8, e81563. doi:10.1371/journal.pone.0081563
59. Negoro N, Sasaki S, Mikami S, Ito M, Suzuki M, Tsujihata Y, Ito R, Harada A, Takeuchi K, Suzuki N, Miyazaki J, Santou T, Odani T, Kanzaki N, Funami M, Tanaka T, Kogame A, Matsunaga S, Yasuma T, Momose Y (2010) Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist. ACS Med Chem Lett 1:290-294. doi:10.1021/ml1000855
60. Ogawa T, Hirose H, Miyashita K, Saito I, Saruta T (2005) GPR40 gene Arg211His polymorphism may contribute to the variation of insulin secretory capacity in Japanese men. Metabolism 54:296-299. doi:10.1016/j.metabol.2004.09.008
61. Ou HY, Wu HT, Hung HC, Yang YC, Wu JS, Chang CJ (2013) Multiple mechanisms of GW-9508, a selective G protein-coupled receptor 40 agonist, in the regulation of glucose homeostasis and insulin sensitivity. Am J Physiol Endocrinol Metab 304:E668-E676. doi:10.1152/ajpendo.00419.2012
62. Pang Z, Wu N, Zhang X, Avallone R, Croci T, Dressler H, Palejwala V, Ferrara P, Tocci MJ, Polites HG (2010) GPR40 is partially required for insulin secretion following activation of beta3-adrenergic receptors. Mol Cell Endocrinol 325:18-25. doi:10.1016/j.mce.2010.04.014
63. Panse M, Gerst F, Kaiser G, Teutsch CA, Dolker R, Wagner R, Haring HU, Ullrich S (2015) Activation of extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) by free fatty acid receptor 1 (FFAR1/GPR40) protects from palmitate-induced beta cell death, but plays no role in insulin secretion. Cell Physiol Biochem 35:1537-1545. doi:10.1159/000373969
64. Parker HE, Habib AM, Rogers GJ, Gribble FM, Reimann F (2009) Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia 52:289-298. doi:10.1007/s00125-008-1202-x
65. Poitout V (2008) Glucolipotoxicity of the pancreatic beta-cell: myth or reality? Biochem Soc Trans 36:901-904. doi:10.1042/bst0360901
66. Poitout V, Robertson RP (2008) Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev 29:351-366. doi:10.1210/er.2007-0023
67. Prentki M, Nolan CJ (2006) Islet beta cell failure in type 2 diabetes. J Clin Invest 116:1802-1812. doi:10.1172/jci29103
68. Prentki M, Matschinsky FM, Madiraju SR (2013) Metabolic signaling in fuel-induced insulin secretion. Cell Metab 18:162-185. doi:10.1016/j.cmet.2013.05.018
69. Qian J, Wu C, Chen X, Li X, Ying G, Jin L, Ma Q, Li G, Shi Y, Zhang G, Zhou N (2014) Differential requirements of arrestin-3 and clathrin for ligand-dependent and -independent internalization of human G protein-coupled receptor 40. Cell Signal 26:2412-2423. doi:10.1016/j.cellsig.2014.07.019
70. Ramos EM, Hoffman D, Junkins HA, Maglott D, Phan L, Sherry ST, Feolo M, Hindorff LA (2014) Phenotype-Genotype Integrator (PheGenI): synthesizing genome-wide association study (GWAS) data with existing genomic resources. Eur J Hum Genet 22:144-147. doi:10.1038/ejhg.2013.96
71. Rankovic Z, Brust TF, Bohn LM (2016) Biased agonism: an emerging paradigm in GPCR drug discovery. Bioorg Med Chem Lett 26:241-250. doi:10.1016/j.bmcl.2015.12.024
72. Schnell S, Schaefer M, Schofl C (2007) Free fatty acids increase cytosolic free calcium and stimulate insulin secretion from beta-cells through activation of GPR40. Mol Cell Endocrinol 263:173-180. doi:10.1016/j.mce.2006.09.013
73. Schroder R, Janssen N, Schmidt J, Kebig A, Merten N, Hennen S, Muller A, Blattermann S, Mohr-Andra M, Zahn S, Wenzel J, Smith NJ, Gomeza J, Drewke C, Milligan G, Mohr K, Kostenis E (2010) Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nat Biotechnol 28:943-949. doi:10.1038/nbt.1671
74. Srivastava A, Yano J, Hirozane Y, Kefala G, Gruswitz F, Snell G, Lane W, Ivetac A, Aertgeerts K, Nguyen J, Jennings A, Okada K (2014) High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. Nature 513:124-127. doi:10.1038/nature13494
75. Steneberg P, Rubins N, Bartoov-Shifman R, Walker MD, Edlund H (2005) The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab 1:245-258. doi:10.1016/j.cmet.2005.03.007
76. Stoddart LA, Brown AJ, Milligan G (2007) Uncovering the pharmacology of the G protein- coupled receptor GPR40: high apparent constitutive activity in guanosine 5’-O-(3-[35S]thio) triphosphate binding studies reflects binding of an endogenous agonist. Mol Pharmacol 71:994-1005. doi:10.1124/mol.106.031534
77. Suckow AT, Polidori D, Yan W, Chon S, Ma JY, Leonard J, Briscoe CP (2014) Alteration of the glucagon axis in GPR120 (FFAR4) knockout mice: a role for GPR120 in glucagon secretion. J Biol Chem 289:15751-15763. doi:10.1074/jbc.M114.568683
78. Sun P, Wang T, Zhou Y, Liu H, Jiang H, Zhu W, Wang H (2013) DC260126: a small-molecule antagonist of GPR40 that protects against pancreatic beta-Cells dysfunction in db/db mice. PLoS One 8, e66744. doi:10.1371/journal.pone.0066744
79. Sunil V, Verma MK, Oommen AM, Sadasivuni M, Singh J, Vijayraghav DN, Chandravanshi B, Shetty J, Biswas S, Dandu A, Moolemath Y, Venkataranganna MV, Somesh BP, Jagannath MR (2014) CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients. BMC Pharmacol Toxicol 15:19. doi:10.1186/2050-6511-15-19
80. Sykaras AG, Demenis C, Case RM, McLaughlin JT, Smith CP (2012) Duodenal enteroendocrine I-cells contain mRNA transcripts encoding key endocannabinoid and fatty acid receptors. PLoS One 7, e42373. doi:10.1371/journal.pone.0042373
81. Tan CP, Feng Y, Zhou YP, Eiermann GJ, Petrov A, Zhou C, Lin S, Salituro G, Meinke P, Mosley R, Akiyama TE, Einstein M, Kumar S, Berger JP, Mills SG, Thornberry NA, Yang L, Howard AD (2008) Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes 57:2211-2219. doi:10.2337/db08-0130
82. Tanaka H, Yoshida S, Oshima H, Minoura H, Negoro K, Yamazaki T, Sakuda S, Iwasaki F, Matsui T, Shibasaki M (2013) Chronic treatment with novel GPR40 agonists improve whole- body glucose metabolism based on the glucose-dependent insulin secretion. J Pharmacol Exp Ther 346:443-452. doi:10.1124/jpet.113.206466
83. Tanaka H, Yoshida S, Minoura H, Negoro K, Shimaya A, Shimokawa T, Shibasaki M (2014) Novel GPR40 agonist AS2575959 exhibits glucose metabolism improvement and synergistic effect with sitagliptin on insulin and incretin secretion. Life Sci 94:115-121. doi:10.1016/j.lfs.2013.11.010
84. Tomita T, Masuzaki H, Iwakura H, Fujikura J, Noguchi M, Tanaka T, Ebihara K, Kawamura J, Komoto I, Kawaguchi Y, Fujimoto K, Doi R, Shimada Y, Hosoda K, Imamura M, Nakao K (2006) Expression of the gene for a membrane-bound fatty acid receptor in the pancreas and islet cell tumours in humans: evidence for GPR40 expression in pancreatic beta cells and implications for insulin secretion. Diabetologia 49:962-968. doi:10.1007/s00125-006-0193-8
85. Tsujihata Y, Ito R, Suzuki M, Harada A, Negoro N, Yasuma T, Momose Y, Takeuchi K (2011) TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. J Pharmacol Exp Ther 339:228-237. doi:10.1124/jpet.111.183772
86. Verma MK, Biswas S, Chandravanshi B, Neelima K, Oommen AM, Jagannath MR, Somesh BP (2014a) A novel GPR40 agonist, CNX-011-67, suppresses glucagon secretion in pancreatic islets under chronic glucolipotoxic conditions in vitro. BMC Res Notes 7:595. doi:10.1186/1756-0500-7-595
87. Verma MK, Sadasivuni MK, Yateesh AN, Neelima K, Mrudula S, Reddy M, Smitha R, Biswas S, Chandravanshi B, Pallavi PM, Oommen AM, Jagannath MR, Somesh BB (2014b) Activation of GPR40 attenuates chronic inflammation induced impact on pancreatic beta-cells health and function. BMC Cell Biol 15:24. doi:10.1186/1471-2121-15-24
88. Vettor R, Granzotto M, De Stefani D, Trevellin E, Rossato M, Farina MG, Milan G, Pilon C, Nigro A, Federspil G, Vigneri R, Vitiello L, Rizzuto R, Baratta R, Frittitta L (2008) Loss-of- function mutation of the GPR40 gene associates with abnormal stimulated insulin secretion by acting on intracellular calcium mobilization. J Clin Endocrinol Metab 93:3541-3550. doi:10.1210/jc.2007-2680
89. Wagner R, Kaiser G, Gerst F, Christiansen E, Due-Hansen ME, Grundmann M, Machicao F, Peter A, Kostenis E, Ulven T, Fritsche A, Haring HU, Ullrich S (2013) Reevaluation of fatty acid receptor 1 as a drug target for the stimulation of insulin secretion in humans. Diabetes 62:2106-2111. doi:10.2337/db12-1249
90. Wagner R, Staiger H, Ullrich S, Stefan N, Fritsche A, Haring HU (2014) Untangling the interplay of genetic and metabolic influences on beta-cell function: examples of potential therapeutic implications involving TCF7L2 and FFAR1. Mol Metab 3:261-267. doi:10.1016/j.molmet.2014.01.001
91. Walker CG, Goff L, Bluck LJ, Griffin BA, Jebb SA, Lovegrove JA, Sanders TA, Frost GS (2011) Variation in the FFAR1 gene modifies BMI, body composition and beta-cell function in overweight subjects: an exploratory analysis. PLoS One 6, e19146. doi:10.1371/journal.pone.0019146
92. Wang Z, Thurmond DC (2009) Mechanisms of biphasic insulin-granule exocytosis - roles of the cytoskeleton, small GTPases and SNARE proteins. J Cell Sci 122:893-903. doi:10.1242/jcs.034355
93. Wang L, Zhao Y, Gui B, Fu R, Ma F, Yu J, Qu P, Dong L, Chen C (2011) Acute stimulation of glucagon secretion by linoleic acid results from GPR40 activation and [Ca2+]i increase in pancreatic islet {alpha}-cells. J Endocrinol 210:173-179. doi:10.1530/joe-11-0132
94. Wang Y, Liu JJ, Dransfield PJ, Zhu L, Wang Z, Du X, Jiao X, Su Y, Li AR, Brown SP, Kasparian A, Vimolratana M, Yu M, Pattaropong V, Houze JB, Swaminath G, Tran T, Nguyen K, Guo Q, Zhang J, Zhuang R, Li F, Miao L, Bartberger MD, Correll TL, Chow D, Wong S, Luo J, Lin DC, Medina JC (2013) Discovery and optimization of potent GPR40 full agonists containing tricyclic spirocycles. ACS Med Chem Lett 4:551-555. doi:10.1021/ml300427u
95. Wauquier F, Philippe C, Leotoing L, Mercier S, Davicco MJ, Lebecque P, Guicheux J, Pilet P, Miot-Noirault E, Poitout V, Alquier T, Coxam V, Wittrant Y (2013) The free fatty acid receptor G protein-coupled receptor 40 (GPR40) protects from bone loss through inhibition of osteoclast differentiation. J Biol Chem 288:6542-6551. doi:10.1074/jbc.M112.429084
96. Xiong Y, Swaminath G, Cao Q, Yang L, Guo Q, Salomonis H, Lu J, Houze JB, Dransfield PJ, Wang Y, Liu JJ, Wong S, Schwandner R, Steger F, Baribault H, Liu L, Coberly S, Miao L, Zhang J, Lin DC, Schwarz M (2013) Activation of FFA1 mediates GLP-1 secretion in mice. Evidence for allosterism at FFA1. Mol Cell Endocrinol 369:119-129. doi:10.1016/j.mce.2013.01.009
97. Yabuki C, Komatsu H, Tsujihata Y, Maeda R, Ito R, Matsuda-Nagasumi K, Sakuma K, Miyawaki K, Kikuchi N, Takeuchi K, Habata Y, Mori M (2013) A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1. PLoS One 8, e76280. doi:10.1371/journal.pone.0076280
98. Zhang J, Ferguson SS, Barak LS, Aber MJ, Giros B, Lefkowitz RJ, Caron MG (1997) Molecular mechanisms of G protein-coupled receptor signaling: role of G protein-coupled receptor kinases and arrestins in receptor desensitization and resensitization. Receptors Channels 5:193-199
99. Zhang Y, Xu M, Zhang S, Yan L, Yang C, Lu W, Li Y, Cheng H (2007) The role of G protein- coupled receptor 40 in lipoapoptosis in mouse beta-cell line NIT-1. J Mol Endocrinol 38:651-661. doi:10.1677/jme-06-0048
100. Zhang X, Yan G, Li Y, Zhu W, Wang H (2010) DC260126, a small-molecule antagonist of GPR40, improves insulin tolerance but not glucose tolerance in obese Zucker rats. Biomed Pharmacother 64:647-651. doi:10.1016/j.biopha.2010.06.008